Traumatic Brain Injury News and Research

RSS
Traumatic brain injury (TBI), a form of acquired brain injury, occurs when a sudden trauma causes damage to the brain. TBI can result when the head suddenly and violently hits an object, or when an object pierces the skull and enters brain tissue. Symptoms of a TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. A person with a mild TBI may remain conscious or may experience a loss of consciousness for a few seconds or minutes. Other symptoms of mild TBI include headache, confusion, lightheadedness, dizziness, blurred vision or tired eyes, ringing in the ears, bad taste in the mouth, fatigue or lethargy, a change in sleep patterns, behavioral or mood changes, and trouble with memory, concentration, attention, or thinking. A person with a moderate or severe TBI may show these same symptoms, but may also have a headache that gets worse or does not go away, repeated vomiting or nausea, convulsions or seizures, an inability to awaken from sleep, dilation of one or both pupils of the eyes, slurred speech, weakness or numbness in the extremities, loss of coordination, and increased confusion, restlessness, or agitation.
New research suggests physical therapy helps restore variety of functions after neurological injury

New research suggests physical therapy helps restore variety of functions after neurological injury

Oxygen Biotherapeutics announces its expanded product development plan

Oxygen Biotherapeutics announces its expanded product development plan

MMPF technique for diagnosing and predicting brain syndromes

MMPF technique for diagnosing and predicting brain syndromes

Vitamin D and progesterone combination for treating traumatic brain injury

Vitamin D and progesterone combination for treating traumatic brain injury

Somanetics obtains exclusive sublicense to new cerebral autoregulation technology

Somanetics obtains exclusive sublicense to new cerebral autoregulation technology

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

NICoE to study how brain works after sustaining combat-related injury using Elekta Neuromag

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

AVANIR Pharmaceuticals announces results of Zenvia double-blind Phase III STAR trial

CED to host popular STREAK program

CED to host popular STREAK program

New device minimizes brain damage by speeding the delivery of post-stroke countermeasures

New device minimizes brain damage by speeding the delivery of post-stroke countermeasures

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

Brain injuries in Ontario's construction industry are highest in August and October

Brain injuries in Ontario's construction industry are highest in August and October

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

AVANIR's STAR trial Phase III data to be presented at the World Congress on Controversies in Neurology

Researchers develop integrated treatment program for PTSD affected veterans

Researchers develop integrated treatment program for PTSD affected veterans

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

SFC Fluidics to develop handheld traumatic brain injury diagnostic device for the U.S. Army

Medical experts explore future of health advancements at Military Medicine Symposium

Medical experts explore future of health advancements at Military Medicine Symposium

Non-accredited education programs for people with chronic disabilities

Non-accredited education programs for people with chronic disabilities

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

Innovative stroke treatment device to minimize brain damage

Innovative stroke treatment device to minimize brain damage

Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma

Phase 3 clinical trials of BHR-100 infusion to be initiated by BHR Pharma